These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 6800533)

  • 21. Selective 5-HT2 receptor blockade in exercise-induced asthma.
    So SY; Lam WK; Kwan S
    Clin Allergy; 1985 Jul; 15(4):371-6. PubMed ID: 3161664
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Haemodynamic and humoral responses to chronic ketanserin treatment in essential hypertension.
    Fagard R; Fiocchi R; Lijnen P; Staessen J; Moerman E; de Schaepdryver A; Amery A
    Br Heart J; 1984 Feb; 51(2):149-56. PubMed ID: 6362688
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chronic 5-HT2-receptor blockade by ritanserin does not reduce blood pressure in patients with essential hypertension.
    Hedner T; Pettersson A; Persson B
    Acta Med Scand; 1987; 222(4):307-10. PubMed ID: 2892349
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ketanserin in hypertension. Early clinical evaluation and dose finding study of a new 5-HT2 receptor antagonist.
    Andrén L; Svensson A; Dahlöf B; Eggertsen R; Hansson L
    Acta Med Scand; 1983; 214(2):125-30. PubMed ID: 6353879
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The antihypertensive effects of a pure and selective serotonin-receptor blocking agent (R 41 468) in elderly patients.
    De Cree J; Leempoels J; De Cock W; Geukens H; Verhaegen H
    Angiology; 1981 Feb; 32(2):137-44. PubMed ID: 7011110
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tone-dependent responses of 5-hydroxytryptamine in the feline pulmonary vascular bed are mediated by two different 5-hydroxytryptamine receptors.
    Neely CF; Haile D; Matot I
    J Pharmacol Exp Ther; 1993 Mar; 264(3):1315-26. PubMed ID: 8450468
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renal effects of ketanserin in essential hypertension.
    Navis G; de Jong PE; van der Hem GK; de Zeeuw D
    J Hypertens Suppl; 1986 Apr; 4(1):S95-8. PubMed ID: 2939222
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Haemorheological effects of ketanserin, a selective 5-HT2 receptor antagonist, in aged, spontaneously hypertensive dogs.
    De Clerck F; Jageneau A; Dom J
    Arch Int Pharmacodyn Ther; 1982 Jul; 258(1):100-15. PubMed ID: 7138138
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Experience with ketanserin and ritanserin in hypertensive patients.
    Hedner T; Persson B
    J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S44-8. PubMed ID: 2459514
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of ketanserin, a new inhibitor of 5-HT2 receptors, on plasma renin activity and aldosterone levels in normal subject.
    Degli Uberti EC; Trasforini G; Margutti AR; Rotola CA; Pansini R
    Horm Res; 1982; 16(4):244-8. PubMed ID: 6751979
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of 5-hydroxytryptamine in endotoxin-induced respiratory failure of pigs.
    Olson NC
    Am Rev Respir Dis; 1987 Jan; 135(1):93-9. PubMed ID: 3541719
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ketanserin: haemodynamic effects and mechanism of action.
    Schalekamp MA; Woittiez AJ; Wenting GJ; van den Meiracker AH; Man in 't Veld AJ
    J Hypertens Suppl; 1986 Apr; 4(1):S7-12. PubMed ID: 2871144
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tryptaminergic receptors in the bovine pulmonary vasculature: effects of ketanserin.
    Ogunbiyi PO; Eyre P
    Res Commun Chem Pathol Pharmacol; 1984 Apr; 44(1):31-55. PubMed ID: 6328601
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ketanserin in essential hypertension: effects during rest and exercise.
    Persson B; Hedner T; Berglund G
    Eur J Clin Pharmacol; 1983; 25(3):307-12. PubMed ID: 6628517
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ketanserin, a novel 5-hydroxytryptamine antagonist: monotherapy in essential hypertension.
    Hedner T; Persson B; Berglund G
    Br J Clin Pharmacol; 1983 Aug; 16(2):121-5. PubMed ID: 6615685
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of a selective 5-HT2 antagonist, ketanserin, on the pulmonary responses to Escherichia coli endotoxin.
    Ball HA; Parratt JR; Rodger IW
    Br J Pharmacol; 1983 Oct; 80(2):295-301. PubMed ID: 6360280
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Haemodynamic consequences of intrinsic sympathomimetic activity in relation to changes in plasma renin activity and noradrenaline during beta-blocker therapy for hypertension.
    Man in't Veld AJ; Schalekamp MA
    Postgrad Med J; 1983; 59 Suppl 3(689):140-58. PubMed ID: 6139800
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ketanserin in combination with beta-adrenergic receptor blocking agents in the treatment of essential hypertension.
    Hedner T; Persson B
    Br J Clin Pharmacol; 1984 Nov; 18(5):765-71. PubMed ID: 6150724
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Central 5-hydroxytryptamine (5-HT) receptors in blood pressure regulation.
    Dabiré H
    Therapie; 1991; 46(6):421-9. PubMed ID: 1819150
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Study with the competitive 5-HT2-serotonergic antagonist ketanserin.
    Ferrara LA; Fasano ML; Rubba P; Soro S; Marotta G; Mancini M
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S159-60. PubMed ID: 2412041
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.